Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine pathological response to a maximum of 18 weeks of
neoadjuvant therapy using a combination of letrozole and Bevacizumab in post-menopausal women
with pathologically confirmed invasive ductal cancer or invasive lobular cancer of the breast
whose tumors are hormone positive.